Denali Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
507
- Stock Symbol
-
DNLI
- Investments
-
3
- Share Price
-
$18.45
- (As of Friday Closing)
Denali Therapeutics General Information
Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Contact Information
Website
www.denalitherapeutics.comCorporate Office
- 161 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 161 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Denali Therapeutics Stock Performance
As of 20-Nov-2026, Denali Therapeutics’s stock price is $18.45. Its current market cap is $2.96B with 160M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $18.45 | $18.20 | $15.34 - $27.30 | $2.96B | 160M | 1.66M | -$1.72 |
Denali Therapeutics Financials Summary
As of 30-Sep-2026, Denali Therapeutics has a trailing 12-month revenue of $21.4M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,625,782 | 1,774,375 | 2,149,081 | 1,910,349 |
| Revenue | 21,382 | 0 | 0 | 330,531 |
| EBITDA | (321,496) | (540,530) | (478,349) | (179,973) |
| Net Income | (314,423) | (512,540) | (422,773) | (145,224) |
| Total Assets | 1,256,035 | 1,144,854 | 1,374,180 | 1,153,917 |
| Total Debt | 29,792 | 36,756 | 48,707 | 52,241 |
Denali Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Denali Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Denali Therapeutics Comparisons
Industry
Financing
Details
Denali Therapeutics Competitors (68)
One of Denali Therapeutics’s 68 competitors is Alector, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Design Therapeutics | Formerly VC-backed | Carlsbad, CA | ||||
| Avidity Biosciences | Formerly VC-backed | San Diego, CA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ |
Denali Therapeutics Patents
Denali Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026169916-A1 | Dosing regimen for a treatment of hunter syndrome | Pending | 05-Feb-2025 | ||
| WO-2026136804-A1 | Compositions and methods for modulating synuclein expression | Pending | 20-Dec-2024 | ||
| WO-2026060081-A1 | Anti-amyloid beta antibodies and methods of use | Pending | 12-Sep-2024 | ||
| WO-2026006173-A1 | Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof | Pending | 24-Jun-2024 | ||
| AU-2025208177-A1 | Chemically modified oligonucleotides and conjugates and methods thereof | Pending | 08-Jan-2024 | C07K19/00 |
Denali Therapeutics Signals
Denali Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Denali Therapeutics Investments & Acquisitions (3)
Denali Therapeutics’s most recent deal was a Merger/Acquisition with F-star Gamma for . The deal was made on 30-May-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| F-star Gamma | 30-May-2018 | Merger/Acquisition | Biotechnology | ||
| Incro Pharmaceuticals | 25-Aug-2016 | Merger/Acquisition | Biotechnology | ||
| F-star Gamma | 05-Jun-2016 | Secondary Transaction - Private | Biotechnology |
Denali Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.23 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Denali Therapeutics FAQs
-
When was Denali Therapeutics founded?
Denali Therapeutics was founded in 2015.
-
Where is Denali Therapeutics headquartered?
Denali Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Denali Therapeutics?
Denali Therapeutics has 507 total employees.
-
What industry is Denali Therapeutics in?
Denali Therapeutics’s primary industry is Biotechnology.
-
Is Denali Therapeutics a private or public company?
Denali Therapeutics is a Public company.
-
What is Denali Therapeutics’s stock symbol?
The ticker symbol for Denali Therapeutics is DNLI.
-
What is the current stock price of Denali Therapeutics?
As of 20-Nov-2026 the stock price of Denali Therapeutics is $18.45.
-
What is the current market cap of Denali Therapeutics?
The current market capitalization of Denali Therapeutics is $2.96B.
-
What is Denali Therapeutics’s current revenue?
The trailing twelve month revenue for Denali Therapeutics is $21.4M.
-
Who are Denali Therapeutics’s competitors?
Alector, Beam Therapeutics, Design Therapeutics, Avidity Biosciences, and Lisata Therapeutics are some of the 68 competitors of Denali Therapeutics.
-
What is Denali Therapeutics’s annual earnings per share (EPS)?
Denali Therapeutics’s EPS for 12 months was -$1.72.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process